Device makers, like pharmaceutical manufacturers, have long recognized that their success depends upon making their products known to physicians who will prescribe or recommend the use of their particular product.
In addition to their ability to influence current product use, physicians also are in the best position to conduct or oversee research that may expand future market share, including identifying additional clinical uses or adaptations for a product — some of which may not yet be approved by the U.S. Food and Drug Administration (FDA).
Read the complete article by clicking on the link below.
Reprinted with permission from Portfolio Media, Inc. This appeared in both Health Law360 and Competition Law360.
Author(s)
Related Insights
Watch On-Demand
Upcoming
Events
Get Anytime Access to Continuing Legal Education and Business Programming
Our new LearningLab: On-Demand Hub offers a growing library of continuing legal education (CLE) and business-focused legal insights you can now access anytime, anywhere.
October 27, 2026
Upcoming
Events
Federal Administrative Sanctions: Suspensions, Revocations, Exclusions, and Civil Monetary Penalties
Foley partner Judy Waltz, chair of the firm’s Health Care Practice Group, is speaking at the upcoming HCCA Healthcare Enforcement Compliance Conference in the session “Federal Administrative Sanctions: Suspensions, Revocations, Exclusions, and Civil Monetary Penalties.”
October 9, 2026
Upcoming
Events
22nd Annual IP Conference
Foley & Lardner LLP is back in Boston for our 22nd Annual IP Conference! Join us on Friday, October 9, 2026, for a full day of insightful discussions led by industry voices from across the corporate and intellectual property landscape. This premier event will explore emerging trends, best practices in IP management, and key legal considerations, providing a valuable opportunity to: